Men should be concerned about declining total testosterone, even if it has not reached a level to warrant a clinical diagnosis (<300 ng/dL [10.4 nmol/L])- stated the researchers.
Low levels of testosterone in men (hypogonadism) could be a cause for the development of chronic diseases including hypertension and diabetes, according to a study published in the journal Scientific Reports. This study was conducted by Mark Peterson, assistant professor of physical medicine and rehabilitation at Michigan Medicine, and colleagues, to determine the association between chronic disease, age, and testosterone.
Testosterone is a male sex hormone which is responsible for men’s physical appearance and sexual activity. After the age of 30, its production starts declining resulting in increased susceptibility of men to a wide range of diseases. Apart from aging, the other factors that contribute to low testosterone production include obesity, medications and pituitary disorders.
“Previous research in the field has shown that total testosterone deficiency in men increases with age, and studies have shown that testosterone deficiency is also associated with obesity-related chronic diseases,” Peterson says. “But it hasn’t been previously understood what the optimal levels of total testosterone should be in men at varying ages, and to what effect those varying levels of the hormone have on disease risk across the life span.”
Using data from the National Health and Nutrition Examination Survey, the research team examined the extent to which hypogonadism is prevalent among men of all ages.Of the 2,399 men in the survey who were at least 20 years old, 2,161 had complete information on demographics (e.g., age, ethnicity and household income), chronic disease diagnoses, blood samples obtained for total testosterone, grip strength and lab results for cardiometabolic disease risk factors.
Peterson and team then examined the prevalence of nine chronic conditions, including type 2 diabetes, arthritis, cardiovascular disease, stroke, pulmonary disease, high triglycerides, hypercholesterolemia, hypertension and clinical depression.
The researchers studied the prevalence of multimorbidity, or when two or more of the chronic conditions were present, among three age groups (young, middle-aged and older men) with and without testosterone deficiency. They found that low total testosterone was associated with multimorbidity in all age groups — but it was more prevalent among young and older men with testosterone deficiency.
“We also found a large dose-response relationship between the age-specific low total testosterone and moderate total testosterone levels and multimorbidity, even after adjusting for obesity and muscle strength capacity,” Peterson says. “Which means that men should be concerned about declining total testosterone, even if it has not reached a level to warrant a clinical diagnosis (<300 ng/dL [10.4 nmol/L]).”
Co-author Aleksandr Belakovskiy, M.D., a resident in family medicine at Michigan Medicine, who helped to design and carry out the study, notes that the results show the need for further testing and research.
“This study showed a robust association between testosterone and multiple medical morbidities that could influence the way we think about testosterone in general practice,” Belakovskiy says. “While these findings cannot prove causation, it does spark the need for better clinical awareness and more research.”
The team hopes the study and its results can serve as a public service announcement for men.
“A lot of men may not be aware of the risk factors for testosterone deficiency because of their current lifestyle,” Peterson says. “And more importantly, that declining levels could be contributing to a silent decline in overall health and increased risk for chronic disease.”
For more details click on the link:
Latest posts by Medha Baranwal (see all)
- AIIMS researchers develop highly sensitive test for TB - November 12, 2018
- Coronary calcium screening a low cost predictor of heart attack - November 12, 2018
- Drug combination effective in treatment of Penile fibrosis - November 12, 2018